Alberto Zaniboni
Fondazione Poliambulanza Istituto Ospedaliero · 665 works · 17,645 citations · h-index 58
Top works
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
- Folinic acid + 5-Fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of ‘GISCAD’ (Italian Group for the Study of Digestive Tract Cancer)
- Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
- The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
- Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer.
- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
- Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
- GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma : final results of the GERCOR /GISCAD Intergroup Phase III
- Association of Obesity With Survival Outcomes in Patients With Cancer
- Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer
- Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators
- Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials
- GIVIO-SITAC 01
- 5-Fluorouracil and High-Dose Folinic Acid as Salvage Treatment of Advanced Breast Cancer: An Update